Assertio Therapeutics, Inc. 소개
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
본사251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
설립2018
상태운영 중
특허특허 1건
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
법적 정보
| 법인명 | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20GLEIF에서 보기 ↗ |
| 등기 주소 | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| 상태 | 운영 중 |
출처: GLEIF · 2026년 10월 16일 업데이트
연락처 및 링크
위치
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
귀하의 회사인가요?
이 페이지를 무료로 신청하여 로고, 제품, 사진, 채용 공고를 추가하고 리뷰에 답변하세요.
이 페이지 신청